Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
MFC$43.24-0.75(-1.70%)Manulife Financial Q3 Earnings Call Highlights1:15:13 PM ETPEP$141.70-1.37(-0.96%)3 Dividend Stocks I'd Buy With $5,000 Before the End of November1:15:00 PM ETORCL$115.98+0.94(+0.82%)Older Nvidia Chips Just Cost Oracle Its Microsoft AI Deal1:08:44 PM ETNVDA$188.70+5.04(+2.78%)Nvidia Stock Has More Than 60% Upside According to Analysts' Average Price Target. Should You Buy While the AI Trade Wobbles?1:00:00 PM ETBRK-B$571.71-1.44(-0.25%)Berkshire Hathaway’s Utility Is Asking for a Historic Rate Hike in California12:49:42 PM ETBRK-A$856,612.00-88.01(-0.01%)Berkshire Hathaway: Abel Just Made The Biggest Buyback In History12:45:30 PM ETBRK-A$856,612.00-88.01(-0.01%)UPDATE 3-Berkshire Hathaway speeds up stock buybacks, though profit falls12:37:14 PM ETUPS$108.50-2.74(-2.47%)After World War I, He Took A Job With A Parcel Delivery Company. He Bought Company Stock Every Year. He Retired From UPS In 1952 And Said He Never Made More Than $14,000 A Year. 39 Years Later Theodore Johnson’s Fortune Was An Estimated $70 Million12:36:11 PM ETNVDA$188.70+5.04(+2.78%)The S&P 500 Just Had Its Worst Week Since the April 2025 Tariff Crash12:33:39 PM ETSKHY$127.90+3.44(+2.78%)Micron and Sandisk Lead the Memory Market. 1 Stock Has Far Greater Upside.12:30:00 PM ETNET$269.32+24.24(+9.91%)Cloudflare, Inc. (NET) Q3 2026 Earnings Call Transcript12:24:35 PM ETWMT$125.25-2.20(-1.72%)Walton Family Gets $100 Billion Richer As Walmart Surges12:18:44 PM ETAMZN$259.83-0.91(-0.35%)Amazon's new basic Kindle proves you don't need all the bells and whistles12:18:00 PM ETTSLA$359.40+14.53(+4.23%)Musk Says His Terafab Chip Plant Could Cost $1 Trillion12:16:41 PM ETHCA$488.00-12.49(-2.46%)HCA Healthcare: 3 Key Takeaways for Long-Term Investors12:15:02 PM ETLOW$224.00-2.69(-1.18%)This Dividend King Yielding 2X the S&P 500 Looks Like a Buy in November.12:15:00 PM ETPEP$141.70-1.37(-0.96%)Here's How Many Shares of PepsiCo You'd Need for $500 in Yearly Dividends12:09:00 PM ETAMD$448.14+44.64(+11.04%)AMD: AI Panic Meets Outsized CPU/GPU Gains - Upgrade To Buy12:00:00 PM ETASTS$32.49+2.13(+7.05%)AST SpaceMobile Is Building Its Own Reusable Rocket to Rely Less on SpaceX11:49:42 AM ETNVDA$188.70+5.04(+2.78%)The Artificial Intelligence (AI) Boom Is Far From Over. Here Are 4 Potential Long-Term Winners11:45:02 AM ETAXP$320.99-3.98(-1.22%)American Express’s CEO Sold $99 Million of Stock the Day Before the Crash11:41:58 AM ETANET$170.80+11.64(+7.31%)Arista Networks vs. Okta: Which Technology Stock Is a Better Buy for 2027?11:37:02 AM ETINTC$56.83+4.03(+7.71%)AI Stocks Are Falling; Bitcoin Is Holding Ground. Here's What Could Come Next.11:31:00 AM ETKO$95.77-0.06(-0.06%)These 5 Consumer Stocks Raised Their Dividends in 2026. Here's What $10,000 in Each Pays in 2027.11:30:00 AM ET
News desk

Live news

Stock news, press releases, and legal notices, plus crypto, forex, and macro (category=crypto, category=forex, category=macro). Over 2.5 million stock articles since 2020. Signed-out visitors and Free accounts see the last year, 15 minutes behind. Pro, including the 7-day trial, sees articles since 2020 as each headline is ingested.

LiveHeadlines show up as soon as they are ingested, with ticker, type, source, and time.

Pro

15-min delayYour Free plan is delayed 15 minutes. Pro opens the live desk.

Start 7-day free trial See live plans

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans

Since 2020This range is older than the last year on your plan. Pro opens articles since 2020.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
CANF Press release Can-Fite to Pursue Global Licensing and Strategic Partnerships at BIO-Europe 2026 Following Recent Clinical and Intellectual Property Milestones GlobeNewswire
CANF Press release Can-Fite Announces Eurasian Patent Allowance Supporting Piclidenoson Development and Commercialization in Lowe Syndrome GlobeNewswire
CANF Press release Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026 GlobeNewswire
CANF Press release Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation GlobeNewswire
CANF Press release Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study GlobeNewswire
CANF Stock news Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study Benzinga
CANF Press release Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds GlobeNewswire
CANF Press release Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study GlobeNewswire
CANF Press release Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer GlobeNewswire
CANF Press release Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates GlobeNewswire
CANF Press release Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome GlobeNewswire
CANF Press release Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology GlobeNewswire
CANF Press release Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer GlobeNewswire
CANF Press release Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027 GlobeNewswire
CANF Press release Wall Street is Watching These Biotechs GlobeNewswire
CANF Press release Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease GlobeNewswire
CANF Press release Can-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson's RAS Signaling Inhibition Mechanism GlobeNewswire
CANF Press release Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson's Potential in the Multi-Billion Dollar Canine Osteoarthritis Market GlobeNewswire
CANF Press release Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market GlobeNewswire
CANF Press release Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy GlobeNewswire
Market Pulse

The stocks the news moved.

Twice a day, a short summary of the names a headline pushed, and the story behind the move.

FAQ

Frequently asked questions

Is the live news desk the same feed as the API?
The desk shows the same articles in the browser: ticker, type, source, and published time. Signed-out visitors and Free accounts see the last year, 15 minutes behind. Pro, including the 7-day trial, sees articles since 2020 as soon as a row is ingested. A Free API key returns the last year. Pro keys search articles since 2020. Both plans return the summary, when it has been written, and the original URL.
Why is the live news desk delayed?
Signed-out visitors and Free accounts see this desk 15 minutes behind ingestion, across the last year of headlines. Pro, including the 7-day trial, sees articles since 2020 as soon as headlines are ingested. A Free API key has the same 15-minute delay. The delay is the plan, not an outage, and the status page stays green while the delayed view is on.
How far back does the live news desk go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, legal notices, and crypto, forex, and macro headlines, 15 minutes behind ingestion. Pro, including the 7-day trial, sees articles since 2020 as new rows are ingested. Page size is 20. A Free API key returns the last year. Pro keys search articles since 2020.
How do I see stock news without the 15-minute delay?
Start the 7-day Pro trial and sign in. A card is required. Pro is $15 a month, or $162 a year, and this desk then shows articles since 2020 as headlines are ingested. Signed-out visitors and Free accounts still see the last year of headlines 15 minutes behind. A Free API key stays at 50 requests a day, the same delay, and the last year. One trial per email.
What do the columns on the news desk mean?
Ticker is the symbol attached to the article. Type is stock news, press release, legal, crypto, forex, or macro. Stock news, press releases, and legal notices are the stock types. Headline is the title. Source is the publisher or wire. Published is the article time in Eastern Time. Page size is 20. The type menu checks the buckets you want on the page.
Can I search the live news desk by ticker?
Yes. The desk has a ticker search, a headline search, a source menu, and a type menu for stock news, press releases, legal notices, crypto, forex, and macro. Those filters stay on this page. The same filters exist on GET /v1/news if you want the JSON, including the summary and the original URL. Page size on the desk is 20.
How often do new stock headlines appear?
Sources are polled every second, including nights and weekends. Pro, including the 7-day trial, sees a row as soon as it is ingested. Signed-out visitors and Free accounts see that same row 15 minutes later. The desk is a browser view of the API feed, not a second dataset.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].